Inactive Instrument

Other languages Sorrento Therapeutics Inc Other OTC

Equities

US83587F1030

End-of-day quote Other OTC Other stock markets
- ^USD	-

Mar. 15	Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	MT
Mar. 12	News Highlights : Top Company News of the Day - Tuesday at 5 AM ET	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	Mar. 15
Motion for Case Dismissal Rejected for Sorrento Therapeutics, Inc.	Mar. 11
Motion for Case Dismissal Filed for Sorrento Therapeutics, Inc.	Feb. 08
Sixth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	Feb. 04
Fifth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	Dec. 17
Sorrento Therapeutics, Inc. Completes Reduction in U.S. Headcount from 123 to 90	Nov. 07
Sorrento Therapeutics, Inc. Announces Termination of the Employment of Elizabeth Czerepak as Its Executive Vice President	Nov. 07
Yuhan Corporation completed the acquisition of 42% stake in ImmuneOncia Therapeutics Inc. from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for $20 million.	Nov. 02
Sorrento Therapeutics, Inc. Announces Resignation of Tammy Reilly from the Board of Directors	23-10-27
Combined Hearing for Disclosure Statement and Plan Approved for Sorrento Therapeutics, Inc.	23-10-18
Fourth Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	23-10-18
Third Motion for Exclusivity Period Extension Approved For Sorrento Therapeutics, Inc.	23-10-05
Scilex Consummates Purchase of Securities Owned by Sorrento Therapeutics	23-09-21
Oramed Pharmaceuticals Inc. cancelled the acquisition of 40.17% stake in Scilex Holding Company from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q).	23-09-20
Scilex Holding's Phase 2 Trial Shows Safety, Efficacy of Treatment for Lower Back Pain	23-09-14
Sorrento Therapeutics, Inc. Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso	23-09-12
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee Patients	23-09-07
Sorrento Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Bonderman's Wildcat seeks to thwart $2.9 bln Consolidated Communications deal	23-07-12
Bonderman's Wildcat seeks to thwart $2.9 bln Consolidated Communications deal	23-07-12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Sorrento Therapeutics Inc Other OTC

Equities

US83587F1030

Other languages

Filters